55,535 Shares in Kenvue Inc. $KVUE Bought by Foyston Gordon & Payne Inc

Foyston Gordon & Payne Inc bought a new position in Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 55,535 shares of the company’s stock, valued at approximately $1,061,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Physician Wealth Advisors Inc. increased its holdings in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares during the period. Elyxium Wealth LLC bought a new stake in Kenvue in the 4th quarter valued at about $26,000. Johnson Financial Group Inc. acquired a new position in Kenvue during the 2nd quarter valued at about $26,000. MV Capital Management Inc. acquired a new position in Kenvue during the 4th quarter valued at about $28,000. Finally, CoreCap Advisors LLC grew its position in Kenvue by 64.9% in the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

KVUE has been the topic of several analyst reports. UBS Group dropped their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Barclays raised their target price on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average price target of $19.27.

Kenvue Price Performance

Shares of Kenvue stock opened at $19.08 on Friday. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $21.78. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The stock has a market cap of $36.65 billion, a PE ratio of 21.93, a price-to-earnings-growth ratio of 1.36 and a beta of 0.47. The company’s 50-day moving average price is $19.05 and its two-hundred day moving average price is $18.19.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01). The business had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the business posted $0.29 EPS. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be issued a dividend of $0.21 per share. The ex-dividend date is Wednesday, August 12th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 dividend on an annualized basis and a yield of 4.4%. Kenvue’s payout ratio is 96.55%.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.